English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17-beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms

Hudert, C. A., Adams, L. A., Alisi, A., Anstee, Q. M., Crudele, A., Draijer, L. G., et al. (2022). Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17-beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms. Hepatology Communications, 2022: 1955. doi:10.1002/hep4.1955.

Item is

Basic

show hide
Genre: Journal Article

Files

show Files
hide Files
:
HepatolComm_Hudert et al_2022.pdf (Publisher version), 2MB
Name:
HepatolComm_Hudert et al_2022.pdf
Description:
-
Visibility:
Public
MIME-Type / Checksum:
application/pdf / [MD5]
Technical Metadata:
Copyright Date:
-
Copyright Info:
© 2022 The Authors

Locators

show

Creators

show
hide
 Creators:
Hudert, Christian A. , Author
Adams, Leon A., Author
Alisi, Anna, Author
Anstee, Quentin M., Author
Crudele, Annalisa , Author
Draijer, Laura G., Author
Furse, Samuel , Author
Hengstler, Jan G., Author
Jenkins, Benjamin , Author
Karnebeek, Kylie , Author
Kelly, Deirdre A., Author
Koot, Bart G. , Author
Koulman, Albert , Author
Meierhofer, David1, Author              
Melton, Phillip E. , Author
Mori, Trevor A. , Author
Snowden, Stuart G. , Author
van Mourik, Indra , Author
Vreugdenhil, Anita , Author
Wiegand, Susanna , Author
Mann, Jake P. , Author more..
Affiliations:
1Mass Spectrometry Facility (Head: David Meierhofer), Scientific Service (Head: Christoph Krukenkamp), Max Planck Institute for Molecular Genetics, Max Planck Society, ou_1479669              

Content

show
hide
Free keywords: -
 Abstract: Genome-wide association studies in adults have identified variants in hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) and mitochondrial amidoxime reducing component 1 (MTARC1) as protective against nonalcoholic fatty liver disease (NAFLD). We aimed to test their association with pediatric NAFLD liver histology and investigate their function using metabolomics. A total of 1450 children (729 with NAFLD, 399 with liver histology) were genotyped for rs72613567T>TA in HSD17B13, rs2642438G>A in MTARC1, and rs738409C>G in patatin-like phospholipase domain-containing protein 3 (PNPLA3). Genotype-histology associations were tested using ordinal regression. Untargeted hepatic proteomics and plasma lipidomics were performed in a subset of children. We found rs72613567T>TA in HSD17B13 to be associated with lower odds of NAFLD diagnosis (odds ratio, 0.7; 95% confidence interval, 0.6-0.9) and a lower grade of portal inflammation (p < 0.001). rs2642438G>A in MTARC1 was associated with a lower grade of hepatic steatosis (p = 0.02). Proteomics found reduced expression of HSD17B13 in carriers of the protective -TA allele. MTARC1 levels were unaffected by genotype. Both variants were associated with down-regulation of fibrogenic pathways. HSD17B13 perturbs plasma phosphatidylcholines and triglycerides. In silico modeling suggested p.Ala165Thr disrupts the stability and metal binding of MTARC1. Conclusion: Both HSD17B13 and MTARC1 variants are associated with less severe pediatric NAFLD. These results provide further evidence for shared genetic mechanisms between pediatric and adult NAFLD.

Details

show
hide
Language(s): eng - English
 Dates: 2022-03-192022-04-11
 Publication Status: Published online
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: DOI: 10.1002/hep4.1955
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Hepatology Communications
  Abbreviation : Hepatol Commun
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: Hoboken, New Jersey : John Wiley & Sons, Inc.
Pages: - Volume / Issue: 2022 Sequence Number: 1955 Start / End Page: - Identifier: ISSN: 2471-254X
PMID: 35411667